Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
ASH 2019: Dr. David Maloney on CAR-T therapy in CLL (chronic lymphocytic leukemia)
By Joseph A. Fraietta, PhD The immune system has many ways to fight cancer, one of which is T cells. A common reason for the failure of the immune system to
Dr. Koffman and Dr. Pleyer discuss the findings from two studies that were previously mentioned in earlier stages of the trial that can be found here. Dr. Pleyer looked at immune response rates in CLL patients after receiving the HEPLISAV-B for preventing hepatitis, and the Shingrix vaccine for preventing shingles.
ASH 2020: Dr. Meghan Thompson Interview – Venetoclax Retreatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
ASH 2020: Dr. Meghan Thompson– Can APR-246 Restore the Wild-Type Function of the P53 Gene in Chronic Lymphocytic Leukemia (CLL)
ASH 2020: Dr. Jennifer Brown on cardiovascular events in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib
ASH 2020: Dr. William Wierda on minimal residual disease (MRD)-guided discontinuation of ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society.
CAR-T is already approved in other blood cancers and more trials are ongoing to expand how it might help patients. Here are three organizations that are providing information and links to raise awareness of CAR-T. There are many others.
One click to our most popular content.
